Amyloid assemblies are associated with a wide range of human disorders, including Alzheimer's and Parkinson's diseases. Here, we identify protein kinase C (PKC) g, a serine/threonine kinase mutated in the neurodegenerative disease spinocerebellar ataxia type 14 (SCA14), as a novel amyloidogenic protein with no previously characterized amyloid-prone domains. We found that overexpression of PKCg in cultured cells, as well as in vitro incubation of PKCg without heat or chemical denaturants, causes amyloid-like fibril formation of this protein. We also observed that SCA14-associated mutations in PKCg accelerate the amyloid-like fibril formation both in cultured cells and in vitro. We show that the C1A and kinase domains of PKCg are involved in its soluble dimer and aggregate formation and that SCA14-associated mutations in the C1 domain cause its misfolding and aggregation. Furthermore, long-term time-lapse imaging indicates that aggregates of mutant PKCg are highly toxic to neuronal cells. Based on these findings, we propose that PKCg could form amyloid-like fibrils in physiological and/or pathophysiological conditions such as SCA14. More generally, our results provide novel insights into the mechanism of amyloid-like fibril formation by multi-domain proteins.
INTRODUCTION
Amyloid aggregates are associated with a great variety of human conditions including Alzheimer's and Parkinson's diseases. The term 'amyloid' was originally used for the extracellular unbranched fibrils that stain with histological dyes such as Congo red in vivo, including amyloid plaques in Alzheimer's disease. However, structurally similar 'amyloid-like' protein fibrils have also been found in many human neurodegenerative disorders such as cytoplasmic Lewy bodies in Parkinson's disease and intranuclear inclusions in polyglutamine diseases. Amyloid and amyloid-like fibrils, despite a lack of sequence and structural similarity in the native states of their component proteins, share common properties (1) (2) (3) (4) . Understanding the mechanism of formation of these aggregates is crucial to develop therapeutics for a wide range of amyloid-related diseases (5) .
Protein kinase C (PKC) is a serine/threonine kinase of thespinocerebellar ataxia type 14 (SCA14) (10, 11) . PKCg consists of an N-terminal regulatory and a C-terminal kinase domain. The regulatory domain of PKCg contains two conserved domains, the diacylglycerol-binding C1 domain and the Ca 2+ -binding C2 domain. The C1 domain is subdivided into the C1A and C1B domains having six conserved cysteines and two histidines in the typical core structure that coordinates two zinc ions. Accumulating evidence suggests that the C1A and C1B domains of PKC have distinct roles in its activation step and translocation (6, 12) . More than 30 mutations in PKCg have been found in SCA14 patients, and most SCA14-associated mutations are found in the C1A and C1B domains of PKCg, although several mutations in the C2 domain and the kinase domain of PKCg have been also reported in SCA14 patients (13) (14) (15) (16) (17) (18) .
Previous studies have revealed that SCA14-associated mutant PKCgs form cytotoxic aggregates in the cytoplasm of primary cultured Purkinje cells as well as mammalian cell lines (19) (20) (21) (22) (23) . Aggregates of mutant PKCg have also been also found in vivo upon lentiviral expression in developing and mature mouse Purkinje cells (24) . The amount of mutant PKCg protein expressed in Purkinje cells was 23% of the endogenous PKCg levels in this in vivo model, suggesting that mutant PKCg could form aggregates in Purkinje cells in heterozygous SCA14 patients, where expression of mutant PKCg should be 50% of the total amount of PKCg (24) . As it is generally believed that SCA14 is caused by a gain-of-function of mutant PKCg, based on several lines of evidence including the data showing PKCg knockout mice with no apparent atrophy in cerebellum, the aggregation of mutant PKCg is thought to play a central role in the pathogenesis of SCA14 (13, 25) .
The aggregation mechanism of mutant PKCg remains, however, unclear. In a screening for compounds that could affect aggregate formation of mutant PKCg, we have recently found that Congo red is very effective in preventing aggregate formation of mutant PKCg (26) . As Congo red preferentially binds to b-sheets containing amyloid and amyloid-like fibrils to inhibit oligomerization (27, 28) , we hypothesized that mutant PKCg aggregates might have characteristics of amyloidlike fibrils. Here, we show that mutant PKCg indeed forms amyloid-like fibrils both in vitro and in cell culture models. Intriguingly, wild-type PKCg was also shown to spontaneously form amyloid-like fibrils, suggesting that SCA14-associated mutations promote, but are not essential for, amyloid-like fibril formation. Mechanistically, native C1A and kinase domains were found to play a critical role in the amyloid-like fibril formation. Our findings thus provide novel insights into the pathogenesis of SCA14 as well as into the mechanism of amyloid fibril formation of multi-domain proteins.
RESULTS

Wild-type and mutant PKCgs form amyloid-like fibrils in cultured cells
The present study was prompted by the recent observation that Congo red is capable of inhibiting the aggregation of the SCA14-causing S119P mutant PKCg (26) . To build on this initial finding, we first examined whether Congo red also affects the aggregation of wild-type and other mutant PKCg (Q127R and V138E) in cells. We utilized two cell lines, Chinese hamster ovary (CHO) cells and human neuroblastoma SH-SY5Y cells, in both of which mutant PKCg has been shown to form aggregates with characteristics that are similar to those of aggregates in primary cultured Purkinje cells (20, 22) . We observed aggregates of PKCg-green fluorescent protein (GFP) in 6% of SH-SY5Y cells overexpressing wildtype PKCg-GFP, whereas overexpression of Q127R or V138E PKCg-GFP increased the cells with the aggregates to 17%. Congo red treatment significantly reduced the aggregation of wild-type PKCg-GFP, as well as Q127R and V138E PKCg-GFP, in SH-SY5Y cells (Fig. 1A) , suggesting that both wild-type and mutant PKCg might form amyloid-like fibrils in cells. To further examine whether PKCg forms amyloid-like fibrils, we performed thioflavin S staining for aggregates of mutant PKCg tagged with DsRed-monomer (PKCg-DRm). Thioflavin S fluorescence was partially co-localized with perinuclear aggregates of mutant PKCg-DRm in CHO cells (Fig. 1B) , whereas it was hardly detected in the perinuclear region of non-transfected CHO cells (Supplementary Material, Fig. S1 ). Furthermore, using electron microscopy (EM), we observed a great number of fibrils in the perinuclear aggregates of both wild-type and mutant (S119P and G128D) PKCg in CHO cells (Fig. 1C-H) . Taken together, these results indicate that overexpression of wild-type PKCg is sufficient to form amyloid-like aggregates in cells and that SCA14-associated mutations promote amyloid-like fibril formation.
Mutant PKCg spontaneously forms amyloid-like fibrils in vitro
We next sought to examine whether the recombinant mutant PKCg forms amyloid-like fibrils in vitro. We purified and utilized glutathione-S-transferase (GST)-tagged full-length Q127R and V138E PKCg ( Fig. 2A) . Western blot analysis revealed that after 24 h of incubation at 378C, recombinant mutant PKCg formed a high-molecular-weight (MW) oligomeric species (.250 kDa). In addition, further incubation (48-72 h) of mutant PKCg yielded SDS-insoluble, high-MW aggregates that did not enter the stacking gel (Fig. 2B) . A concomitant decrease of monomeric forms was also detected, suggesting that high-MW aggregates are mainly formed from monomeric PKCg, possibly via high-MW oligomers. Glutathione-S-transferase alone did not show any high-MW aggregates after 72 h of incubation (Supplementary Material, Fig. S2 ). These high-MW aggregates have frequently been observed in other disease-causing proteins, such as polyglutamine-expanded huntingtin in Huntington's disease that forms amyloid-like fibrils (29) . When mutant PKCg was observed after 3-10 days of incubation under EM, a number of amorphous aggregates (Fig. 2C ) and several long straight filaments ( Fig. 2D-G) were found. Some fibrils appeared to grow from amorphous aggregates (Fig. 2E) . Interestingly, some of the fibrils appeared to exhibit a twisted two-filament architecture (Fig. 2F ) reminiscent of amyloid b fibrils formed in vitro (30) . We also performed a thioflavin T (ThT) binding assay. Thioflavin T binds to b sheets in amyloid oligomers, producing a characteristic fluorescent emission at 482 nm (31) . Thioflavin T fluorescence increased over time (Fig. 2H) , a characteristic of amyloids. Thioflavin T fluorescence also started to decline after 8 days, indicating the formation of large fibers that do not bind efficiently to ThT. We also found that the treatment with Congo red reduces high-MW aggregate formation of recombinant V138E PKCg (Fig. 2I) . Thus, these results clearly showed that recombinant mutant PKCg spontaneously forms aggregates in vitro with characteristic amyloid features.
Wild-type PKCg also forms amyloid-like fibrils in vitro
We also considered whether recombinant GST-tagged wild-type PKCg forms amyloid-like fibrils in vitro. Similar high-MW aggregates were also consistently detected 72 h after incubation of wild-type PKCg ( Fig. 3A and B) . Electron microscopy analysis also showed several long straight twisted fibrils in the incubated sample of GST-tagged wild-type PKCg (Fig. 3C ). These data indicate that wild-type PKCg also spontaneously forms amyloid-like fibrils and that SCA14-associated mutations are not essential for amyloid-like aggregation in vitro. To examine whether SCA14-associated mutations affect the amyloid-like fibril formation, we performed the ThT binding assay using lower concentrations of recombinant wild-type and Q127R PKCgs. Under these conditions, ThT fluorescence was only slightly increased in wild-type PKCg, whereas there was an increase in the ThT fluorescence in Q127R PKCg, suggesting that a SCA14-associated mutation promotes amyloid-like fibril formation of PKCg in vitro (Fig. 3D ). To further examine whether endogenous wild-type PKCg could form aggregates in vivo, we performed western blot analysis using the TBS-soluble, the Triton-soluble and the Tritoninsoluble fractions of the mouse cerebellum. Anti-PKCg antibodies detected an immunoreactive monomer band in the Triton-insoluble fraction. In addition, similar to our in vitro data, high-MW aggregates band was detected in the total and the Triton-insoluble fractions. Interestingly, we also detected high-MW oligomers band ( 250 kDa) in all fractions except the Triton-insoluble fraction (Fig. 3E ). These results suggest the possibility that endogenous wild-type PKCg could form amyloid-like aggregates in vivo.
Prediction of aggregation-prone regions in PKCg
We next sought to understand the mechanisms whereby wild-type and mutant PKCg forms amyloid-like fibrils. As PKCg has no previously characterized amyloid-prone domains, we first utilized the Zyggregator method, which predicts the regions that promote the aggregation of structured globular proteins or proteins that contain both structured and unstructured domains (32) . The method revealed that wild-type PKCg has many potential aggregation-prone regions (Fig. 4) . The aggregation-prone regions were relatively concentrated in the C1A, the C1B and the kinase domains, which seemed to be correlated with the locations of SCA14-associated mutations (Fig. 4) . These predictions also suggest that native C1A, C1B and kinase domains of PKCg might play a critical role in the amyloid-like fibril formation of both wild-type and mutant PKCg.
The C1A and kinase domains are involved in soluble dimerization and aggregation of mutant PKCg Based on the prediction described earlier, we hypothesized that the C1A, the C1B or the kinase domain may also play a critical role in the aggregate formation of PKCg. To test the idea, we focused on V138E PKCg, a mutant PKCg with a mutation in the C1B domain, because most SCA14-associated mutations are found in the C1B domain. We first performed co-transfection studies using V138E PKCg-DRm and each of the GFP-tagged domains: GFP-tagged C1A, C1B, C2 or kinase domains (C1A-GFP, C1B-GFP, C2-GFP or KD-GFP, respectively). We found that C1A-and KD-GFP, but not C1B-and C2-GFP, were significantly incorporated into the aggregates of V138E PKCg-DRm (Fig. 5A ). Consistent with these results, wild-type PKCg-GFP is also incorporated with V138E PKCg-DRm aggregates. Similar results from reversed experiments using V138E PKCg-GFP and each DRm-tagged domain excluded the possibility that DRm was sticky and had an affinity toward C1A-and KD-GFP (Supplementary Material, Fig. S3A ). These findings suggest that intact C1A and kinase domain may be involved in aggregate formation of mutant PKCg, even in PKCg with a C1B domain mutation.
As soluble dimers and/or oligomers are formed before insoluble aggregates in most neurodegenerative-associated proteins (33,34), we examined whether mutant PKCg forms soluble dimers and/or oligomers. To this end, we performed co-immunoprecipitation (co-IP) assays with a Triton-soluble fraction of COS-7 cells. The co-IP assays with full-length PKCg showed self-association of wild-type PKCg. In addition, we found that SCA14-associated mutations dramatically promote self-association of full-length PKCg ( Fig. 5B and Supplementary Material, Fig. S3B ). The co-IP assays using domains from PKCg revealed three possible self-association regions, specifically C1A-C1A domains, C1A-kinase domains and kinase-kinase domains interactions (Supplementary Material, Fig. S4A-D) . The C1A and the kinase domain, but not the C1B or the C2 domain, also interacted with full-length V138E PKCg (Fig. 5C ). These results suggest that the C1A and the kinase domains of mutant PKCg with a C1B domain mutation are involved in the soluble dimer formation that eventually leads to its aggregation. The co-IP assays using mutated domains showed that mutations in C1B (V138E), C1A (R41P) and kinase domain (F643L) could not alter its interaction partners (Supplementary Material, Fig. S4E -G). We next sought to gain insight into the effects of SCA14-associated mutations on aggregate formation. We focused on the C1 domain of PKCg, because most SCA14-associated mutations of PKCg are located within C1A and C1B that bind to membrane diacylglycerol or tumor-promoting phorbol esters (Figs. 4 and 6A). To examine whether SCA14-associated mutations affect the function and folding of the C1 domain, we performed an in vitro [ 3 H]phorbol 12,13-dibutyrate (PDBu)-binding assay using wild-type and mutated C1A and C1B peptides as previously reported (35) . We did not examine the C1 domains with mutations at cysteine residues, such as C114Y and C131R, because these mutations were assumed to cause the complete loss of PDBu-binding ability by causing their inability to coordinate zinc, as reported in a previous study (36) . Consistent with a previous study, the K d values of wildtype C1A and C1B peptide were 1.36 and 1.2 + 0.06 nM, respectively (35) . In contrast, the K d values of mutated C1A and C1B peptides were significantly higher. In addition, several mutated C1A or C1B peptides (R41P, G63V, Q127R and G128D) showed no PDBu-binding ability (Table 1) . Notably, none of SCA14-associated mutations we tested increased the PDBubinding ability of the C1 domain. These results indicate that SCA14-associated mutations impair the PDBu-binding ability of the C1A or C1B domain of PKCg and suggest that the mutations in the C1 domain might cause its misfolding.
SCA14-associated mutations impair the [
SCA14-associated mutations in C1 domain cause its aggregation in cells
To determine whether the mutations in C1 domain cause its misfolding, we examined whether mutated C1A, C1B or whole C1 domain alone forms aggregates using CHO cells expressing C1A-, C1B-or C1-GFP. Compared with wild-type C1A-GFP and C1B-GFP, all tested mutated C1A-GFP (R41P and G63V C1A-GFP) and C1B-GFPs (H101Y, C114Y, S119P and V138E C1B-GFP) except Q127R C1B-GFP tended to form aggregates in the perinuclear region of CHO cells ( Fig. 6B and C), although their size was relatively smaller than the full-length mutant protein aggregates previously reported (19) . Moreover, GFP-tagged mutated whole C1 domains also formed perinuclear aggregates (Fig. 6D ). These data support the possibility that the mutations in C1 domain cause its misfolding and also suggest that mutated C1 domain may be directly involved in the aggregate formation of mutant PKCg.
Aggregation of mutant PKCg is highly cytotoxic
We next sought to understand the relationship between mutant PKCg aggregation and cytotoxicity. We performed long-term time-lapse imaging of living SH-SY5Y cells expressing mutant PKCg-GFP with the LCV-100 or LCV-110 incubation imaging system, which enables to monitor several individual cells transfected with several distinct plasmids as well as the same plasmid over time at the same time in an independent experiment. Four mutants (R41P, H101Y, Q127R and F643L) were selected to determine whether mutant PKCg can form toxic aggregates, regardless of the location of the mutation (i.e. the C1A, the C1B or the kinase domain). These mutations were selected because they have also been found in a relatively large number of SCA14 patients (37) (38) (39) . Individual cells transfected with these four mutant PKCg-GFPs were monitored 1 day after transfection for 22 h. Similar to previous studies with CHO cells and primary cultured Purkinje cells (20, 22) , it was observed that several cells, in which no visible aggregates were initially detected, formed cytoplasmic aggregates of mutant PKCg-GFP. The formation of these aggregates was followed by shrinkage, an early apoptotic-like morphological change (40) , and complete detachment from the cultured dish ( Fig. 7A and Supplementary Material, Movie S1). We first examined the survival time of all cells that died within the observation period after aggregate formation of mutant PKCg-GFPs. Cell death was defined as irreversible detachment from the cultured dish after shrinkage because we have previously observed caspase activation as well as ubiquitin-proteasome system impairment and ER stress in cells that exhibit this type of behavior (20) . Surprisingly, more than 80% of cell deaths with visible mutant PKCg aggregates were caused within 10 h after aggregate formation. In addition, similar results were obtained with four different mutant PKCg-GFPs ( Fig. 7B and Human
Supplementary Material, Movies S2-S4). We subsequently examined the lifespan of individual cells, with or without visible aggregates 1 day after transfection, and determined the level of difference using survival analysis for 10 h, as previously reported (41) . The survival analysis showed that in the four different mutant PKCg-GFPs-expressing cells, cells with visible mutant PKCg-GFP aggregates died faster than cells without aggregates ( Fig. 7C-F) . These results indicate that aggregate formation of at least four different mutant PKCgs is highly cytotoxic.
We also examined the relationship between cytotoxicity and fluorescent intensity of diffuse mutant PKCg-GFP. The survival time of individual cells with diffuse mutant PKCg-GFP was not correlated with their maximum GFP fluorescent intensity on the first day after transfection in all of four of the different mutant PKCg-GFPs (Fig. 7C-F, Inset) . We further examined the lifespan of individual cells expressing diffuse wild-type PKCg-GFP, Q127R PKCg-GFP or non-fused GFP in another set of four independent experiments. Diffuse Q127R PKCg-GFP was equally as cytotoxic as diffuse wild-type PKCg-GFP, whereas diffuse non-fused GFP was significantly less cytotoxic ( Fig. 7G and H) . Similar results were obtained with cells expressing wild-type and Q127R PKCg fused to the C-terminus of mCherry (Supplementary Material, Fig. S5A -C) , excluding 
532
Human Molecular Genetics, 2015, Vol. 24, No. 2 the possibility that the cytotoxic effects of mutant PKCg are specific to mutant PKCg fused to the N-terminus of GFP. These results revealed that the aggregation process plays a role in the cytotoxic effects of mutant PKCg.
DISCUSSION
In this study, we identified PKCg, a kinase associated with spinocerebellar ataxia, as a novel amyloidogenic protein with no previously characterized amyloid-prone domains.
The mechanisms of amyloid-like fibril formation of PKCg
Our results indicate that the C1A and kinase domains are involved in the soluble dimer and aggregate formation of wildtype and mutant PKCg with C1B mutation. The co-IP assay also showed that C1A -C1A, C1A -kinase and kinase -kinase domains interactions may represent the common intermolecular interaction sites of mutant PKCg. It is possible that the C1A -kinase domains interaction is also an intra-molecular interaction site of PKCg, although a recently published crystal structure of full-length PKCbII isoform showed only the C1B -kinase domains interaction (42) . Three-dimensional structures of full-length PKCg are yet to become available. Access to these structures would help understand the conformation and aggregation process of wild-type and mutant PKCg. It is well known that the C1 domains are highly hydrophobic and involved in protein -protein interactions as well as lipidprotein interactions (12) . The kinase domain also contains several hydrophobic regions (6) . These hydrophobic regions therefore may mediate the dimerization and aggregation of PKCg.
In this study, we have shown that SCA14-associated mutations promote the amyloid-like fibril formation of PKCg both in cells and in vitro. There are several possible explanations about how SCA14-associated mutations enhance aggregation. Our results indicate that several SCA14-associated mutations in C1 domain impair its phorbol ester binding, suggesting that mutations in the C1 domain cause improper folding, probably by diminishing zinc coordination and/or perturbing the stability of the secondary and tertiary structures. Mutated C1A or C1B domains alone were also shown to form small aggregates in CHO cells. Therefore, first, mutated C1 domain may directly contribute to the aggregate formation of mutant PKCg, as described later. Second, the mutations in the C1 domain might cause cytoplasmic accumulation of PKCg by impairing its membrane diacylglycerol binding. Third, most importantly, the improper folding of the C1 domain may destabilize the inactive (closed) conformation of full-length PKCg, which may enhance inter-molecular interactions and amyloid-like fibril formation. This idea is supported by previous studies showing that most mutant PKCg-GFPs are constitutively active (23, 43, 44) . Verbeek and colleagues have also suggested that SCA14 mutations in C1B 'open' PKCg protein conformation (45) . SCA14-associated mutations in the kinase domain (G360S, S361G and F643L) also increase aggregate formation of PKCg (13, 19) . We have shown that these kinase domain mutations increase the formation of soluble dimers. As a previous study has suggested that kinase domain mutations in PKCl may affect the overall conformation of the protein (46), the kinase domain mutations in PKCg may also destabilize the closed conformation by disrupting intra-molecular interactions and promote inter-molecular interactions.
Taken together, we propose the following mechanisms whereby wild-type and mutant PKCg (mainly for C1B mutations) forms amyloid-like fibrils (Fig. 8) . SCA14-associated mutations may affect native folding of C1B domain to cause cytosolic accumulation and to destabilize closed conformation of PKCg, which may expose buried inside regions of C1A and kinase domains of mutant PKCg. Newly exposed regions of C1A and kinase domains in turn cause aberrant inter-molecular interaction of mutant PKCg via C1A-C1A domains, C1A-kinase domains and kinase-kinase domains interactions. These intermolecular interactions may promote oligomerization, aggregation and amyloid-like fibril formation of mutant PKCg. This model for amyloid-like fibril formation may be, at least in part, supported by previously published 'Gain-of-interaction models', where a 3D domain swapping like C1A-kinase domains interaction has been suggested (47) . We have shown that mutated C1B-GFP forms aggregates in cells, suggesting that mutated C1B alone has an ability to directly form cross-b spine and amyloid-like fibrils. Recently, in Huntington's disease, N-terminal 17 amino acids of huntingtin were shown to promote polyglutamine expansions to form amyloid (48, 49) . Similarly, C1A and kinase domains might support and promote mutated C1B domain to form cross-b spine. While most mutated C1B domains formed aggregates, we did not observe aggregates of the C1B domain with the Q127R mutation despite robust aggregation of full-length Q127R PKCg in cells. These results suggest that the mechanism of aggregate formation of full-length Q127R PKCg may be different from other C1B mutants and that the aggregation of full-length Q127R PKCg may not require the C1B domain aggregation caused by its misfolding. In addition, the results also suggest that the inter-molecular interactions, rather than mutated C1B domain aggregation, might play a critical role in aggregate formation of full-length mutant PKCg. With regard to wild-type PKCg, repetitive physiological stimuli may destabilize the closed conformation, which could lead to intermolecular interactions and aggregation of wild-type PKCg.
The relationship between PKCg aggregates and cytotoxicity
It is still under debate whether amyloid or amyloid-like aggregates are pathogenic, incidental or protective in many neurodegenerative diseases (50) . Recently, soluble oligomers, rather than larger aggregates, have been proposed as the agents responsible for neurodegeneration (33, 34) . We have previously demonstrated that aggregate formation of S119P and G128D mutant PKCg impairs the ubiquitin-proteasome system and induces endoplasmic reticulum stress in cultured Purkinje cells, leading to apoptotic cell death (20, 22) . In the current study, using long-term time-lapse imaging analysis, we have confirmed and expanded our previous studies. It was directly demonstrated that regardless of the location of the mutation (R41P, H101Y, Q127R or F643L), the aggregation of mutant PKCg is highly cytotoxic. We have also observed early apoptotic-like morphological change, which is consistent with a previous study (40) . In addition, the time from visible aggregate formation to cell death was markedly similar in the four different mutant PKCgs examined. All SCA14-mutant PKCgs therefore may form amyloid-like aggregates to cause apoptotic cell death. A conversion process from soluble to insoluble aggregates may be highly cytotoxic because diffuse mutant PKCg-GFP was equally as cytotoxic as diffuse wild-type PKCg-GFP. This conclusion is also supported by the observation that most cells rapidly died after visible mutant PKCg aggregates were formed. In contrast to SH-SY5Y and cultured Purkinje cells, apoptotic cell death has not been observed in Purkinje cells having mutant PKCg aggregates in vivo (24) . However, our preliminary EM analysis showed 'dark cell' degeneration in Purkinje cells of mice lentivirally expressing mutant PKCg but not in Purkinje cells expressing GFP, suggesting that mutant PKCg aggregates might be toxic to Purkinje cells in vivo as well (Supplementary Material, Fig. S6A and B) . We have also found abnormal binucleated 10 .0 + 2.7, 14.4 + 4.5, 19.7 + 5.0 and 25.3 + 7.3 (mean + SD) cells without aggregates of mutant PKCg (R41P, H101Y, Q127R and F643L, respectively) in each experiment [ * P , 0.05; * * P , 0.0001 (inset)]. In individual cells without aggregates, the maximum fluorescent intensity of mutant PKCg-GFP was measured on the first day after transfection and plotted against their respective survival times. (G and H) These experiments were performed separately from the experiments described in Figure 6A -F. Therefore, the setting of GFP fluorescent intensity in these experiments was different from that of Figure 6A -F. Neuroblastoma SH-SY5Y cells were transfected with GFP, wild-type PKCg-GFP or Q127R PKCg-GFP. One day after transfection, pictures were taken every 15 min and the data were analyzed using MetaMorph software, as described in Materials and Methods. All data were obtained from four independent experiments. We could evaluate 25.3 + 1.7, 34.8 + 7.3 and 23.5 + 4.8 (mean + SD) cells expressing diffuse GFP, wild-type PKCg-GFP and Q127R PKCg-GFP, respectively, in each experiment. (G) The mean 10-h survival rate of cells expressing diffuse GFP, wild-type PKCg-GFP and Q127R PKCg-GFP. Data are shown as mean + SEM (n ¼ 4).
* P , 0.05, * * * P , 0.001 (ANOVA, Tukey's test). Diffuse wild-type PKCg-GFP was equally as cytotoxic as diffuse Q127R PKCg-GFP (n.s., not significant). These were also more cytotoxic than GFP alone. (H) In individual cells without aggregates, the maximum GFP fluorescent intensity was measured on the first day after transfection and plotted against their respective survival times. The survival time of individual cells with diffuse wild-type or Q127R PKCg-GFP was not correlated with their maximum GFP fluorescent intensity on the first day after transfection (Spearman, not significant). Figure 8 . Hypothetical model of amyloid-like fibril formation of PKCg. SCA14-associated mutations in the C1 (C1A or C1B) domain may cause improper folding by diminishing zinc coordination and/or perturbing the secondary and tertiary structure. The improper folding of the C1 domain may destabilize the closed conformation of PKCg. In cells, the impaired membrane-binding ability of the C1 domain may also cause cytoplasmic accumulation of PKCg. The destabilized PKCg may expose buried inside regions of its C1A and kinase domains. Then, newly exposed regions of the C1A and kinase domains in turn cause aberrant inter-molecular interaction of PKCg via C1A-C1A domains, C1A -kinase domains and kinase-kinase domains interactions. These interactions may promote oligomerization, aggregation and amyloid-like fibril formation of mutant PKCg. Other factors such as PKCg-interacting proteins may also affect self-association of PKCg in cells.
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Purkinje cells expressing mutant PKCg-GFP but not wild-type PKCg-GFP in vivo (Supplementary Material, Fig. S6C ). Taken together, our findings support the idea that amyloidlike oligomers and fibril formation of mutant PKCg may contribute to SCA14 pathogenesis like other neurodegenerative diseases and provide amyloid-like fibril formation as a novel potential therapeutic target. It will be interesting to see whether mutant PKCg amyloid oligomers and fibrils indeed exist and whether they are associated with severe atrophy of the cerebellum observed in SCA14 patients, although SCA14 is a rare and is not a lethal disease, which limits the availability of the postmortem tissues of the patients.
Potential roles of amyloid-like fibril formation of wild-type PKCg
We have shown that wild-type PKCg forms amyloid-like aggregates in vitro. We have also found high-MW aggregates of endogenous PKCg in the total and the Triton-insoluble fractions of the mouse cerebellum. By using cells without transfection, it has long been known that prolonged activation by phorbol ester causes accumulation of PKCs in the detergent-insoluble fraction of cells (6, 51, 52) . More specifically, endogenous PKCg has been shown to translocate to the detergent-insoluble fraction in response to glutamate in primary hippocampal neurons (53) . These previous studies as well as the current one suggest that some fractions of endogenous PKC isoforms might form amyloid-like aggregates in cells under physiological conditions. Until now, this possibility has not been investigated in detail. Amyloid is not always pathological but rather has normal physiological functions (3) . PKCs may form amyloid-like aggregates to amplify their local signals in some physiological PKC-dependent pathways, as proposed in several intracellular signaling proteins (54) . We anticipate that the current study will promote further research to clarify these issues.
MATERIALS AND METHODS
Plasmid construction
Wild-type and several mutant PKCg-GFPs or PKCg-DRms have been described previously (18, 43) . For GFP-, DRm-, mCherry-, Myc-and FLAG-tagged constructs, full-length human PKCg, C1A (amino acids 26-89 or 26-100 for pcDNA3.1-Myc), C1B (98 -154 or 86 -159 for pcDNA3.1-Myc), C2 (156 -333) and kinase (318-697) domains were used. They were subcloned into pUC118 (TaKaRa) and then cloned into pcDNA3, pcDNA3.1-Myc, pmCherry-C1 (Clontech) and p3XFLAG-CMV-10 (Sigma). Mutations in each domain were also generated using the QuikChange II XL sitedirected mutagenesis kit. All PCR products were verified by sequencing. The molecular size of mutants and domains was verified by immunoblot analysis using anti-PKCg, anti-GFP, anti-FLAG (M2) and anti-Myc (9E10) antibodies.
Cell culture and transfection SH-SY5Y, CHO, HeLa and COS-7 cells were maintained in Ham/DMEM containing Glutamax, Ham, MEM and DMEM, respectively. All media were supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin. Transient transfection was performed with Lipofectamine 2000 (Invitrogen) for SH-SY5Y cells or FuGENE TM 6 (Roche) for COS-7, HeLa and CHO cells. Sf9 cells were cultured in EX-CELL TM 420 (JRH Bioscience) containing 10% fetal bovine serum and 0.5% antibiotic/antimycotic (Invitrogen) and maintained in suspension as shaker cultures.
Long-term time-lapse imaging
Long-term time-lapse imaging was performed using a computerassisted fluorescent microscope, the LCV100 or LCV110 incubation imaging system (Olympus, Tokyo, Japan). This device possesses the ability to monitor fluorescence in living cells under normal culture conditions (378C, 95% humidity and 5% CO 2 ). After 1 day of transfection, GFP or mCherry fluorescence of SH-SY5Y cells was observed for 20 or 22 h. Sequential GFP or mCherry fluorescence and DIC images of SH-SY5Y cells were obtained every 15 min and analyzed using MetaMorph software (Molecular Devices Corporation, PA, USA). For Figure 6A -F, the maximum fluorescent intensity of cells with diffuse R41P, H101Y, Q127R, or F643L PKCg-GFP at 15 min before aggregate formation was 739 + 144, 773 + 165, 772 + 162 or 832 + 161 (mean + s.d.), respectively. In order to reduce the effect of the expression level of PKCg-GFP, we therefore evaluated all cells having diffuse mutant PKCg-GFP with maximum fluorescent intensity of .700 at the starting point of observation. The experiments for Figure 6G and H were performed separately from those described in Figure 6A -F. Therefore, the setting of GFP fluorescent intensity in these experiments was different from that of Figure 6A -F. To reduce the effect of the expression level of PKCg-GFP, we evaluated cells with maximum relative GFP fluorescent intensity of 800-1500 at the starting point of observation. Statistical difference in Kaplan-Meier curves was assessed with the log-rank test using GraphPad Prism software.
Synthesis of mutated C1B peptides and in vitro [ 3 H]PDBu-binding assay As mutated C1B peptides are synthesized and purified in the absence of zinc, zinc coordination of these peptides was first carried out as previously reported (35) . The PDBu-binding assay was performed by the method described by Sharkey and Blumberg (55) , with slight modifications (35) . In brief, zinc coordination was carried out in a distilled water solution for each C1 peptide using 5 M equivalent of ZnCl 2 at 48C. After dilution with distilled water, an aliquot of the peptide solution (2.9 ml for 20 nM; 29 ml for 200 nM) was added to the reaction mixture (247.1 ml for 20 nM; 221 ml for 200 nM) consisting of 50 mM Tris -Maleate (pH 7.0 -7.4), 10 mg/ml g-globulin, 50 mg/ml 1,2-dioleoylsn-glycerol-3-phospho-L-serine and 20 nM [ 
Observation of protein aggregates
DRm-or GFP-tagged mutant PKCg and DRm-or GFP-tagged domain (C1A, C1B, C2 and KD-GFP) were co-transfected into SH-SY5Y, HeLa and CHO cells. Transfected cells were cultured in glass bottom dishes for 1 -2 days until observation. The fluorescence of GFP or DsRed was observed using a Zeiss LSM 
Co-immunoprecipitation and immunoblot analysis
COS-7 cells were co-transfected with FLAG-tagged wild-type PKCg, mutant PKCg, the C1A, the C1B, the C2 or the kinase domain, and Myc-tagged wild-type PKCg, mutant PKCg, the C1A, the C1B, the C2 or the kinase domain. One day after transfection, COS-7 cells were washed once, harvested with ice-cold PBS and resuspended in ice-cold TBS-T (150 mM NaCl, 0.5% Triton X-100 and 50 mM Tris-HCl; pH 7.4) containing 20 mg/ ml leupeptin and 1 mM phenylmethylsulfonyl fluoride (PMSF). After homogenization using a sonicator, the cell lysates were cleared by centrifugation for 15 min at 15 000g at 48C. The supernatants were incubated for 2 h at 48C with anti-Myc (9E10) or anti-FLAG (M2) monoclonal antibodies. Protein complexes were collected with the addition of protein A-sepharose beads (GE Healthcare Bio-Sciences, AB, Uppsala, Sweden) for 1 h at 48C. Immunoprecipitates were washed at least four times with an ice-cold homogenization buffer or TBS-T and then were added to 2× SDS sample buffer and boiled for 5 min at 958C. Immunoblot analysis was performed with anti-Myc (9E10) or anti-FLAG (M2) antibody. Quantification of band intensity was performed using Scion image software.
Recombinant protein expression and purification
Recombinant baculoviruses encoding GST-tagged Q127R, V138E or wild-type PKCg were prepared according to the manufacturer's instruction (Novagen). About 3 -4 days after infection, Sf9 cells were collected and washed once with ice-cold PBS and resuspended in ice-cold TBS-T containing 20 mg/ml leupeptin and 1 mM PMSF. After homogenization using a sonicator, the cell lysates were cleared by centrifugation for 15 min at 15 000 g at 48C. The supernatants were incubated for 4 h at 48C with glutathione -Sepharose 4B resin (GE Healthcare Bio-Sciences). After washing six times with ice-cold TBS-T, the bound proteins were eluted with 50 mM Tris-HCl and 20 mM reduced glutathione at pH 8.0. The recombinant proteins were dialyzed three times against 50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1 mM EDTA and 1 mM DTT and stored at 2808C until use. In western blot and electron microscopic analyses, 1 mM PMSF and 1 mM leupeptin were added to 50 ml of the protein solution (15 -75 mg/ml) during incubation without shaking at 378C.
Electron microscopy
For purified protein, samples were spread on carbon-coated grids and negatively stained with 1% uranyl acetate and then observed and photographed using a Hitachi 7100 electron microscope (Tokyo, Japan) with an acceleration voltage of 75 kV. For cultured cells, Ad-CMV-tTA, Ad-TetOp-wild-type PKCg-GFP and Ad-TetOp-S119P PKCg-GFP were constructed as previously described (26) . The CHO cells were spread on 6-cm (5 × 10 5 cells/dish) dishes. After 24 h of cultivation, cells were infected with two adenoviral vectors, Ad-CMV-tTA and wild-type or S119P Ad-TedOp PKCg-GFP, at a multiplicity of infection of 10 and cultured for another 3 days. The cells were washed, harvested and fixed with 5% glutaraldehyde in PBS. After washing out of fixing solution, the cell pellets were re-fixed in 2% osmium tetraoxide in PBS, dehydrated through a graded series of ethanol and then flat-embedded on siliconized slides in Epon. After polymerization at 508C for 24 h and at 608C for 24 h, the areas of our interest were cut off and attached to Epon supports for further sectioning on a Reichert-Jung Ultracut E ultramicrotome. Ultrathin sections were mounted on 200-mesh collodion grids (TAAB), stained with 2% uranyl acetate and Reynold's solution and then observed and photographed under a Hitachi 7100 electron microscope.
Thioflavin T fluorescence assay
Sample solution consisting of a recombinant protein, 1 mM PMSF, 1 mM leupeptin and 5 mM thioflavin T was incubated in Sanyo CO 2 incubator model MCO-17A1C (Sanyo Electric Co. Ltd, Osaka, Japan) at 378C. The sample solution was shaken using a Model 2330 mixer (Wakenyaku Co. Ltd., Kyoto, Japan) during the incubation, and the solution was used for fluorescence measurements. Thioflavin T fluorescence was monitored by Jasco fluorimeter FP (Jasco Co., Tokyo, Japan).
Thioflavin S staining
Two days after transfection, CHO cells expressing mutant PKCg-DRm were fixed with 4% paraformaldehyde for 30 min at room temperature. Subsequent procedures were performed at room temperature. After washing three times with PBS containing 0.03% Triton X-100 (PBS-T), the cells were treated with PBS containing 0.3% Triton X-100 for 45 min and subsequently stained with 0.001% thioflavin S (Sigma). After washing four times with PBS-T, the cell images were observed with an inverted epi-fluorescence microscope, the Nikon Eclipse TS100F (Nikon Instruments, Tokyo, Japan), equipped with a CCD camera, the Digital Sight DS-2MBVc (Nikon). Filter blocks of G-2A and BV-2A were used for visualizing DRm and thioflavine S, respectively.
Prediction of aggregation-prone regions
The prediction of aggregation-prone regions was performed with the Zyggregator method as previously reported (32).
Brain protein extraction
All animal studies were approved by the Institutional Animal Care and Use Committee and conducted according to the Kobe University Animal Experimentation Regulations. The cerebellums of C57BL/6N male mice were dissected out and homogenized by sonication in ice-cold TBS (50 mM Tris -HCl, 150 mM NaCl, 1 mM EDTA, pH 7.4) containing a protease inhibitor cocktail (Nakalai Tesque). A portion of the homogenate was stored as the total fraction. After centrifugation at 100 000g for 30 min at 48C, the supernatant was stored as the TBS-soluble fraction. The pellet was washed with ice-cold TBS three times and resuspended by sonication to the same volume as the original homogenate in TBS with 1% Triton Human Molecular Genetics, 2015, Vol. 24, No. 2 537 X-100 containing a protease inhibitor cocktail. After centrifugation at 100 000g for 30 min at 48C, the supernatant was stored as the Triton-soluble fraction. The pellet was washed and resuspeded by sonication to the same volume in TBS with 2.5% SDS containing a protease inhibitor cocktail and stored as the Triton-insoluble fraction. SDS -PAGE was performed in a nonreducing condition (without mercaptoethanol).
